Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19

BMJ Case Rep. 2021 May 24;14(5):e243315. doi: 10.1136/bcr-2021-243315.

Abstract

We describe the case of a 65-year-old male who presented to an outside hospital for shortness of breath, nausea and vomiting 8 days after testing positive for COVID-19. Initial workup revealed massive bilateral pulmonary emboli and thrombocytopenia. The patient was then admitted to our hospital, received an inferior vena cava filter and initially started on argatroban for autoimmune heparin-induced thrombocytopenia (HIT) prophylaxis. On hospital stay day 6, labs revealed a diagnosis of HIT in the setting of COVID-19. This case highlights the rare occurrence of a patient developing HIT without heparin exposure and in the setting of a novel infectious agent, COVID-19.

Keywords: COVID-19; haematology (drugs and medicines); haematology (incl blood transfusion).

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anticoagulants / adverse effects
  • COVID-19*
  • Heparin / adverse effects
  • Humans
  • Male
  • Pipecolic Acids
  • SARS-CoV-2
  • Thrombocytopenia* / chemically induced

Substances

  • Anticoagulants
  • Pipecolic Acids
  • Heparin